Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu

At Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu, research in Hemic and Lymphatic Diseases focuses on blood cancers and related disorders, with studies aimed at improving treatment options, response rates, and patient outcomes.

• Studies in acute myeloid leukaemia are exploring more effective, personalized treatment strategies for newly diagnosed patients.
• Trials in myelodysplastic syndrome are evaluating new ways to improve anemia control and reduce the need for transfusions.
• Research in hemophilia A and hemophilia B is assessing preventive therapies to better manage bleeding risk.

The site’s hematology team is contributing to research that aims to refine care for both malignant and non-malignant blood disorders.

The oncology portfolio at this hospital includes trials for aggressive and relapsed cancers, especially large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and classical Hodgkin lymphoma, with a strong emphasis on testing newer treatment approaches.

• Studies in diffuse large B-cell lymphoma are comparing emerging therapies with standard care to improve disease control.
• Trials in relapsed or refractory lymphomas are examining options for patients whose disease has returned or resisted prior treatment.
• Research in follicular lymphoma is evaluating novel combinations to improve long-term remission and response.
• Work in classical Hodgkin lymphoma is focused on finding more effective choices after earlier therapies have failed.

Overall, the site is active in testing new therapies for hematologic malignancies and in comparing them with established treatment standards.